anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Risk Summary

There are no adequate and well-controlled studies with moxifloxacin ophthalmic solution in pregnant women to inform any drug-associated risks.

Oral administration of moxifloxacin to pregnant rats and monkeys and intravenously to pregnant rabbits during the period of organogenesis did not produce adverse maternal or fetal effects at clinically relevant doses. Oral administration of moxifloxacin to pregnant rats during late gestation through lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses (see DATA). 

Data

Animal Data

Embryo-fetal studies were conducted in pregnant rats administered with 20, 100, or 500 mg/kg/day moxifloxacin by oral gavage on Gestation Days 6 to 17, to target the period of organogenesis. Decreased fetal body weight and delayed skeletal development were observed at 500 mg/kg/day [277 times the human area under the curve (AUC) at the recommended human ophthalmic dose]. The No-Observed-Adverse-Effect-Level (NOAEL) for developmental toxicity was 100 mg/kg/day (30 times the human AUC at the recommended human ophthalmic dose).

Embryo-fetal studies were conducted in pregnant rabbits administered with 2, 6.5, or 20 mg/kg/day moxifloxacin by intravenous administration on Gestation Days 6 to 20, to target the period of organogenesis. Abortions, increased incidence of fetal malformations, delayed fetal skeletal ossification, and reduced placental and fetal body weights were observed at 20 mg/kg/day (1086 times the human AUC at the recommended human ophthalmic dose), a dose that produced maternal body weight loss and death. The NOAEL for developmental toxicity was 6.5 mg/kg/day (246 times the human AUC at the recommended human ophthalmic dose).

Pregnant cynomolgus monkeys were administered moxifloxacin at doses of 10, 30, or 100 mg/kg/day by intragastric intubation between Gestation Days 20 and 50, targeting the period of organogenesis. At the maternal toxic doses of ≥ 30 mg/kg/day, increased abortion, vomiting, and diarrhea were observed. Smaller fetuses/reduced fetal body weights were observed at 100 mg/kg/day (2864 times the human AUC at the recommended human ophthalmic dose). The NOAEL for fetal toxicity was 10 mg/kg/day (174 times the human AUC at the recommended human ophthalmic dose).

In a pre- and postnatal study, rats were administered moxifloxacin by oral gavage at doses of 20, 100, and 500 mg/kg/day from Gestation Day 6 until the end of lactation. Maternal death occurred during gestation at 500 mg/kg/day. Slight increases in the duration of pregnancy, reduced pup birth weight, and decreased prenatal and neonatal survival were observed at 500 mg/kg/day (estimated 277 times the human AUC at the recommended human ophthalmic dose). The NOAEL for pre- and postnatal development was 100 mg/kg/day (estimated 30 times the human AUC at the recommended human ophthalmic dose).
OBJECTIVE: Several monoclonal antibodies (MoAbs) targeting specific type 2 immune reactions have been developed as innovative therapeutic approaches for chronic inflammatory airway diseases, such as chronic sinusitis with nasal polyps (CRSwNP) and asthma. However, the clinical safety of these MoAbs and how to choose them are not clear. Therefore, we aimed to assess the systemic drug- and dose-based safety of MoAbs in chronic airway inflammation using network meta-analysis (NMA).
METHODS: Electronic databases were systematically searched for relevant studies published in English between January 2009 and December 2022. Eligible studies must have clearly reported adverse events (AEs) among the MoAbs' safety data.
RESULTS: 1). Regarding serious AEs, mepolizumab was significantly safer than placebo; in terms of permanent treatment discontinuation, reslizumab and dupilumab were significantly safer than benralizumab. 2). Regarding asthma worsening, dupilumab was associated with the best safety profile; was safer than dupilumab/300 mg/q2-4w. 3). In terms of injection-site reactions, dupilumab posed a higher risk than placebo; dupilumab/300 mg/qw posed a higher risk than dupilumab/300 mg/q2w and dupilumab/300 mg/q2-4w; lebrikizumab/250 mg/q4w posed a higher risk than lebrikizumab/37.5 mg/q4w; mepolizumab/100 mg/q4w posed a higher risk than mepolizumab/75 mg/q4w; benralizumab/30 mg/q4-8w posed a higher risk than benralizumab/20 mg/q4-8w. 4) In CRSwNP patients combined with asthma, the risks of experiencing AEs were not increased.
CONCLUSION: Overall, biologics are safe and well tolerated in chronic inflammatory airway disease. This drug- and dose-based NMA provides further evidence on the different safety profiles of different emerging MoAbs. This information may help guide rational drug use and provide clinical recommendations for choosing MoAbs.
TRIAL REGISTRATION: SYSTEMATIC REVIEW REGISTRATION (PROSPERO #CRD42023387610).
Participants will receive belzutifan 120 mg orally once daily (QD). Treatment will continue until progressive disease or discontinuation.
Each participant randomized to the intervention arm (MyIBD) will receive an individually tailored MyIBD document within a week of a scheduled outpatient clinic visit. The MyIBD document will be prepared by the patient's usual, assigned nurse coordinator together with the study's clinical champion (a nurse practitioner in the IBD program). Participants will receive a copy of the MyIBD document with language suggesting that they use it to guide decisions about care in between appointments. Each participant's primary care provider will also receive a copy of the MyIBD document. The nurse coordinator will send reminder messages to intervention-group participants (using the electronic patient portal) to access and use their MyIBD document at 1-2 months, 3-4 months, 7-8 months, and 11-12 months after initial plan creation.
This study is a prospective, single arm, pre-approval study. Treatment of 10 patients will take place at 1-3 clinical centers in two phases. Phase 1 will include treatment of five patients with a three month stent indwell period at one clinical center. Phase 2 will include treatment of five additional patients with a 3-6 month stent indwell period at 1-3 clinical centers. Expected duration of participation for each patient is approximately 27 months for Phase 1 and approximately 27-30 months for Phase 2. All patients, regardless of phase, will be followed for 24 months after stent removal. Post-removal follow-up visits will occur at 1, 3, 6, 12, 18 and 24 months.
The invention provides a novel haemophilus parasuis disease trivalent inactivated vaccine and a preparation method thereof. The vaccine comprises equal proportions of antigens of: inactivated haemophilus parasuis serotype 4 JS strain, inactivated haemophilus parasuis serotype 5 ZJ strain, and inactivated haemophilus parasuis serotype 12 HeB strain. According to the invention, the haemophilus parasuis serotype 4, serotype 5, and serotype 12 strains are obtained by separation. Concentration contents and relative proportions of the antigens prepared from the three strains are subjected to large amounts of woks and practices, such that the trivalent vaccine with an appropriate antigen ratio and an appropriate concentration is obtained. The trivalent vaccine has good preventing and treating effects against haemophilus parasuis diseases caused by various epidemic haemophilus parasuis serotypes in our nation. Especially, the trivalent vaccine can solve a problem of poor treatment effect of existing vaccines caused by novel haemophilus parasuis pathogens.
In one visit RCT (Arm 1): The teeth were anesthetized, isolated and endodontic access and instrumentation of all canals was done. Canal preparation was conducted using a step-back technique. The working lengths were determined and confirmed by radiography. Sterile normal saline solution was used for intra-canal irrigation. Root canals were obturated with gutta-percha and sealer using lateral condensation technique. After placing a cotton pellet in the pulp chamber, the access cavity was closed with Cavit.

In pulpotomy treatment with CEM/MTA (Arm 2): The teeth were anesthetized. Pulpotomy procedure of removing inflamed pulp tissue to the stump level was done. Homeostasis was achieved by irrigating the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The pulpal wound was covered with an approximately 2-mm-thick layer of MTA/CEM cement. Pulp chambers were then covered with a wet cotton pellet and sealed with Cavit.
PURPOSE:The titled cosmetic having improved feeling in use and functional characteristics, obtained by blending an oilu makeup cosmetic with organic modified montmorillonite clay and a dextrin fatty acid ester, etc. as a gelatinizing agent. CONSTITUTION:An oily makeup cosmetic comprising 30-70wt% oily raw material and 10-60wt/ powder is blended with 0.2-1.5wt%, preferably 0.3-1wt% organic modified montmorillonite clay and 1-20wt%., preferably 3-15wt% dextrin fatty acid ester and/or lipophilic sucrose fatty acid ester as a gelatinizing agent. Addition of 0.1-5wt% hydrophilic substance such as water-soluble high polymer, hydrophilic surface active agent, etc. and/or 1-30wt% water imprves further feedling in use and functional characteristics. The cosmetic has improved soft feeling in use, and good spread, has feeling of neither oiliness nor greasiness, shows improved adhesivity to the skin, covering power, provides the skinwith moisture and slightly causes makeup collapse.
One embodiment discloses a computerized method of facilitating cardiac intervention. The method may include inputting patient data and creating a computerized interactive model of a heart based on the patient data. The model may include features. The model may simulate at least one proposed cardiac intervention by adding or deleting features to the model, and determining the effects of the proposed cardiac simulation upon the entire model. Simulations may be repeated to allow the user to determine an optimal cardiac intervention. A template and/or patient specific instrument may be created from the model to use as a guide during the cardiac intervention.
Provided are a makeup cosmetic which can have bright fluorescent colouring whilst still having excellent transparency (being clear), and a novel cosmetic colouring material that is suitable for the cosmetic. The present invention provides a makeup cosmetic comprising (A) at least one kind of oil-soluble dye selected from the group consisting of red no. 218, red no. 223 and orange no. 201, (B) particles of a specific material selected from hydroxyapatite, calcium carbonate, a metal oxide (other than ferric oxide) and silica, and (C) oil, wherein the blending amount of pigment is not greater than 0.5 mass%, and the blending amount of water is less than 1.5 mass%. The makeup cosmetic, according to the present invention, can achieve high luminance fluorescent colouring whilst also having excellent transparency, and can be used as a lip cosmetic, blusher or eye shadow.
Avascular necrosis (AVN) is a debilitating condition characterized by bone tissue death due to inadequate blood supply, leading to joint dysfunction and collapse. This study investigates the potential association between AVN and COVID-19, focusing on genetic factors such as NOS3 polymorphisms. A total of 180 individuals were included, comprising 120 COVID-19 patients and 60 healthy controls. Clinical, haematological, biochemical, and genetic parameters were assessed. Results revealed significant differences in respiratory and heart rates, haematological counts, and biochemical markers between AVN and control groups. Genetic analysis showed a higher prevalence of the TG genotype and G allele in NOS3 rs1799983 polymorphism among AVN patients. Additionally, NOS3 rs2070744 polymorphism correlated with various clinical parameters, including blood pressure, heart rate, and haematological indices. This study highlights the potential role of genetic factors in predisposing individuals to AVN following COVID-19 infection.
PURPOSE:To obtain the titled antibody, produced by a hybridoma prepared using an outer membrane protein C (OmpC) of Escherichia coli as an immunologi cal source and capable of directly detecting Gram-negative bacilli mixed in a sample, e.g. biological sample or food, etc., without pretreatment by heating. CONSTITUTION:A blend prepared by blending OmpC or a crude outer membrane fraction of Escherichia coli containing the OmpC with complete or incomplete Freund's adjuvant is injected into an animal, e.g. mouse, etc., to carry out sensitization and splenic cells or lymphocytic B cells extracted from the immunized animal are fused to myelomatous cells. The aimed specific antibody-producing cells are selected from the fused cells and cloned to provide a hybridoma capable of producing the aimed antibody. The above-mentioned antibody is cultivated in a normal culture medium for animal cells and reacted with OmpC trimer to afford a monoclonal antibody unreactive with the OmpC monomer and OmpC trimer. The afore-mentioned antibody is capable of linking to live cells of Escherichia coli and Citrobacter freundii.
The invention provides a natural medicament composition applied to a medicament for preventing and treating bone loss diseases. The composition has an extremely good effect of suppressing formation of osteoclast. The natural medicament composition can be used for preparing a medicament for treating the bone loss diseases such as osteoporosis. The composition comprises the following components in parts by weight: 2-10 parts of flos carthami, 3-10 parts of astragalus membranaceus, 1-10 parts of puerarin, 3-8 parts of radix rehmanniae preparata and 4-7 parts of eucommia. Components with effects of suppressing the formation of the osteoclast can be separated from the materials by various organic solvent extraction methods and separation methods and are combined to prepare the composition for preventing the osteoporosis. The composition disclosed by the invention has an extremely good effect of suppressing the formation of the osteoclast, has poor side effects due to natural medicaments and has a function of safety to use; furthermore, the composition is scientific and reasonable in formula; resources of the components are rich; the extraction methods are simple; the natural medicament composition is favorable for industrial production.
The Pelvic Girdle Questionnaire is the only specific instrument designed to evaluate pain and activity limitations in pregnant or postpartum women with pelvic girdle pain. This study aimed to translate the Pelvic girdle questionnaire in Urdu language for Pakistani female patients and to verify the validation of the psychometric items of the Pelvic girdle questionnaire in population of Pakistan. The purpose of this study was to translate the Pelvic Girdle Questionnaire into Urdu and find out cross-culture validity and reliability of Urdu Pelvic girdle questionnaire among pregnant and postpartum females. A cultural adaptation and translation study was performing according to international guidelines. Study was conducted at different hospital settings. Pre test was conducted among 16 females during pregnancy \& post-partum.

Key words: Disability Evaluation, Female, Urdu, Pelvic Girdle Pain and physiopathology, Pregnancy, Surveys and Questionnaires, Translation.
Allogeneic hematopoietic stem cell transplant (HSCT) recipients. Blood samples will be drawn prior to transplantation and every two weeks, up to day 100 post-transplantation.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of renal failure. The pathogenesis of the disease encompasses several pathways and metabolic alterations, including the hyperactivation of mTOR and suppression of AMPK signaling pathways, as well as mitochondrial dysfunction. This metabolic reprogramming makes epithelial cyst-lining cells highly dependent on glucose for energy and unable to oxidize fatty acids. Evidence suggests that high-carbohydrate diets may worsen the progression of ADPKD, providing the rationale for treating ADPKD patients with calorie restriction and, in particular, with ketogenic dietary interventions, already used for other purposes such as in overweight/obese patients or in the treatment of refractory epilepsy in children. Preclinical studies have demonstrated that calorie restriction may prevent and/or slow disease progression by inducing ketosis, particularly through increased beta-hydroxybutyrate (BHB) levels, which may modulate the metabolic signaling pathways altered in ADKPK. In these patients, although limited, ketogenic intervention studies have shown promising beneficial effects. However, larger and longer randomized controlled trials are needed to confirm their tolerability and safety in long-term maintenance and their additive role in the therapy of polycystic kidney disease.
This study is a randomized controlled multi-center clinical trial to determine whether very low birth weight infants should receive feedings during indomethacin or ibuprofen treatment of a patent ductus arteriosus (PDA). Many neonatologists withhold feeds from premature infants receiving indomethacin or ibuprofen therapy for a PDA because of concerns that these drugs alter intestinal blood flow and permeability. However, there are no established studies which show that feeding during these medical treatments leads to bowel injury. At the same time, studies suggest that withholding feedings from premature infants may lead to intestinal atrophy and injury, leading to increased difficulty with feedings when they are initiated or re-started. Thus, this multi-center study evaluates whether feeding infants during indomethacin or ibuprofen therapy improves feeding tolerance by measuring the number of episodes of feeding intolerance and the number of days required to attain full feedings. In addition, this study will employ techniques to measure gastrointestinal permeability and mesenteric blood flow in patients who receive and don't receive feedings for their PDA treatment.
BACKGROUND: Regenerative endodontic procedures (REPs) are innovative treatments aimed at restoring damaged dental structures. However, the effect of orthodontic movement on REP-treated teeth is not well understood and may have significant long-term consequences. This study aimed to evaluate the impact of orthodontic movement on a mature permanent tooth associated with dens invaginatus that has undergone a regenerative endodontic procedure (REP).
CASE PRESENTATION: This report describes the case of a 13-year-old healthy male who presented with pulp necrosis and a chronic apical abscess (tooth number 2.2). Following REP according to the American Association of Endodontists' guidelines, the patient began non-extraction orthodontic treatment with fixed appliances after a 9-month healing period, which lasted 17 months in the upper arch. Subsequent follow-ups at 24, 36 and 48 months post-REP revealed an asymptomatic state with minimal cervical discoloration and diminished cold sensitivity. Radiographic analyses revealed periapical healing, mild apical remodeling on tooth 2.2, and moderate apical remodeling on other maxillary incisors. The treated tooth displayed a positive response to both REP and orthodontic treatment, yet further research is required to determine the long-term effects of orthodontics on REP-treated teeth.
CONCLUSION: Orthodontic movement following REPs in mature permanent teeth is feasible and do not seem to prone teeth to orthodontic tooth resorption. Our experience indicates that a 9-month healing period allows successful orthodontic outcomes following REPs. Nonetheless, the predictability of outcomes and the ideal healing period before orthodontic movement is initiated remain to be established.
PURPOSE: A diaryl hepatonoid compound having virus suppression activity is provided to use in treating diseases relating virus. CONSTITUTION: A pharmaceutical composition for treating and/or preventing diseases caused by virus infection contains a compound of chemical formula I, its isomer or pharmaceutically acceptable salt, their solvate, hydrate or prodrug as an active ingredient. In the chemical formula I, R1, R2, R3, and R4 is independently hydrogen, hydroxyl, C1-C6 alkyl or C1-C6 alkoxy. The compound of the chemical formula I is isolated from organic solvent fraction of Alnus japonica extract. The composition is administered by oral, nasal cavity, abdominal cavity injection or intraocular injection. The daily dose of the composition is 0.5~1000 mg/kg.
In 2019, over 460 million adults had diabetes worldwide. Moreover, it was estimated by the International Diabetes Federation that about 700 million adults will have type 2 diabetes (T2D) by 2045. Valbiotis is a research \& development company dedicated to scientific innovation for preventing and reducing the risk of metabolic and cardiovascular disease (CVD) using specific combinations of plant-based molecules. Valbiotis developed a formula (TOTUM-63) which is composed by the association of five plant extracts.

Given the results obtained in pre-clinical studies, as well as the good tolerance and first efficacy results of TOTUM-63 in two clinical trials on human subjects, this research aims to investigate the effects of TOTUM-63 on cardiometabolic health and gut microbiota profile in overweight-obese individuals. TOTUM-63 will be tested (5g acutely and 5g/d over 8 weeks of supplementation) on energy metabolism, post-prandial nutrients metabolism and hepatic health in overweight and obese subjects. Blood and feces samples collected before, and after the supplementation will allow to perform metabolomic, transcriptomic and metagenomics analyses to further explore the potential mechanisms of action of TOTUM-63.
Amantadine hydrochloride, USP is designated chemically as 1 adamantanamine hydrochloride. Its molecular weight is 187.71 with a molecular formula C10H18NCl. It has the following structural formula.

Amantadine hydrochloride, USP is a stable white or nearly white crystalline powder, freely soluble in water and soluble in alcohol and in chloroform.

Amantadine hydrochloride, USP has pharmacological actions as both an anti-Parkinson and an antiviral drug.

Each capsule intended for oral administration contains 100 mg amantadine hydrochloride and has the following inactive ingredients: D&C Yellow No. 10, gelatin, glycerin, hydrogenated vegetable oil, lecithin, simethicone, soybean oil, titanium dioxide and white wax. The black imprint ink ingredients are hypromellose, iron oxide black, propylene glycol and purified water.
Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. No participants in this group will receive any phone coaching.
NEW MATERIAL:A hydantoin derivative expressed by formula I (R represents H or Cl) or salts thereof. EXAMPLE:1-(2,5-Dichlorophenylsulfonyl) hydantoin. USE:A strong aldose-reductase inhibitor, useful as an inhibitor against diabetic complications (for example, cataract, neuropathy, retinopathy and nephrosis), with low toxicity and usable by oral administration. PREPARATION:A substituted-phenylsulfonyl chloride expressed by formula II is reacted with glycine to obtain N-(substituted-phnylsulfonyl) glycine. Thus obtained compound is reacted with ammonium thiocyanate to form a thiohydantoin derivative. The derivative is further oxidized to obtain the compound expressed by formula I.
Floor mounts and/or floor mount enclosures for a medical computer are disclosed. An example floor mount may include an enclosure framework having a first base, a second base, and a top panel. The second base may be angled. A computer compartment may be defined adjacent the first base. The computer compartment may be configured to house a medical computer therein. An accessory compartment may be defined adjacent the second base. An arcuate rim may be disposed along an end region of the top panel.